Carlsbad, California (PRWEB) September 27, 2013
Groundbreaking research published this week in the Journal of Behavioral and Brain Science* (JBBS) shows that the nutraceutical Endorphinate® is a clinically effective and safe treatment for chronic emotional and physical distress, including anxiety, anger, depression, cravings, and pain hypersensitivity.
Developed by a team of scientists associated with mind-body healing pioneer and endocrinologist Deepak Chopra, M.D., and world-renowned neurologist and Alzheimer’s researcher Dr. Rudolph Tanzi, Endorphinate is a scientific formulation of health-promoting plant extracts and amino acids that is produced and distributed worldwide by Pondera Pharmaceuticals, Inc. Endorphinate® has a direct effect on endorphins, which are natural brain chemicals that create a sense of calm, pleasure, and wellbeing. Endorphinate® combines specific agents that increase the release of endorphins with agents that switch endorphin receptors from an excitatory (distress/pain) to an inhibitory (calm/comfort) mode.
As the peer-reviewed study published in JBBS describes, a team of scientists led by Dr. Stanley M. Crain, Professor Emeritus, Dept. of Neuroscience, Albert Einstein College of Medicine, and Dr. Steven Crain, neuropsychotherapist carried out a 26-month study to assess the benefits of Endorphinate® for individuals suffering from moderate-to-severe emotional and/or physical distress. Through direct treatment and close clinical supervision by Dr. Steven Crain, researchers conducted 203 clinical case studies of both females and males ranging in age from 14 to 85.
The study found that Endorphinate® provided strong clinical benefits, including reduced anxiety, anger, depressed mood, pain hypersensitivity, and cravings. Most participants reported greater calm, comfort, well-being, and pleasure as well as increased mental clarity, energy, productivity, healthier lifestyle choices, and an adaptive response to life’s stresses.
“It’s wonderful to have scientific data supporting the benefits of a natural, non-prescription supplement like Endorphinate®,” said Deepak Chopra. “I have been taking Endorphinate® every day for over a year and have been experiencing its beneficial effects. It has become the number one dietary supplement used by our clients and patients at the Chopra Center. I unhesitatingly endorse and support the use of Endorphinate® to help increase resistance to stress, anxiety, trauma, cravings, and fatigue."
*Steven Crain, Matthew A. Crain, and Stanley M. Crain, “Emotional and Physical
Distress Relief Using a Novel Endorphinergic Formulation,” Journal of Behavioral and Brain Science, Vol. 3, Issue 6, 2013, pp. 441-453. (Link to Article)
For press inquiries and interviews about the science of endorphins and the new study of Endorphinate published in the Journal of Behavioral and Brain Science, contact:
Steven Crain, Ph.D.
Neuropsychotherapist, Therapeutic Alliance
Clinical Director, Pondera Pharmaceuticals Inc.
315 S. Allen St., Suite 422
State College, PA 16801
For press inquiries about Deepak Chopra and the Chopra Center for Wellbeing, please contact:
Chopra Center Marketing Director
About Deepak Chopra, M.D., F.A.C.P.
Founder of the Chopra Center for Wellbeing
Deepak Chopra, M.D. is the author of more than 65 books, including numerous New York Times bestsellers. His medical training is in internal medicine and endocrinology, and he is a Fellow of the American College of Physicians, a member of the American Association of Clinical Endocrinologists, and an adjunct professor of Executive Programs at the Kellogg School of Management at Northwestern University. He is also a Distinguished Executive Scholar at Columbia Business School, Columbia University, and a Senior Scientist at the Gallup organization. For more than a decade, he has participated as a lecturer at the Update in Internal Medicine, an annual event sponsored by Harvard Medical School’s Department of Continuing Education and the Department of Medicine, Beth Israel Deaconess Medical Center.
Read the full story at http://www.prweb.com/releases/2013/9/prweb11168691.htm.
Copyright©2012 Vocus, Inc.
All rights reserved